I'll do an updated graphic later tonight [done!] (the one at right is a projected 2011 -- we now have actuals), but Vertex also announced its Q4 2011 results this morning, and. . . Q4 2011 Incivek sales were $456.8 million. That's better than the 80-20 split, I earlier predicted.
Merck's Victrelis sold just $87 million in Q4 2011. That makes the share split for Q4 about 84 percent for Vertex; 16 percent for Merck. Ouch.
The Vertex presser:
. . . .Net Product Revenues from INCIVEK:Net product revenues for INCIVEK for the fourth quarter of 2011 were $456.8 million. Vertex reported $419.6 million in net product revenues for INCIVEK in the third quarter of 2011. . . .
Recall that Merck reported only $53 million in Q3 2011 sales for Victrelis. Thus, life to date, the split is running at about 85 Vertex, 15 Merck. And that is a legacy Hassan "star"?! Oops.
3 comments:
The sales force is completely disengaging. The company's problems are deep from the inside out and situations like this one are bringing them out into the light.
I can't stand working here anymore....selling for co infection now just to try and get buisness. I have a 22% share and it's not moving.
I do hear you both.
Pretty discouraging.
Thanks for taking the time to write, just the same.
Namaste
Post a Comment